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Background: Cervical lesions caused by integrated human papillomavirus (HPV) infection are highly dangerous
because they can quickly develop into invasive cancers. However, clinicians are currently hampered by the lack of a
quick, convenient and precise technique to detect integrated/mixed infections of various genotypes of HPVs in the
cervix. This study aimed to develop a practical tool to determine the physical status of different HPVs and evaluate
its clinical significance.
Methods: The target population comprised 1162 women with an HPV infection history of > six months and an
abnormal cervical cytological finding. The multiple E1-L1/E6E7 ratio analysis, a novel technique, was developed
based on determining the ratios of E1/E6E7, E2/E6E7, E4E5/E6E7, L2/E6E7 and L1/E6E7 within the viral genome.
Any imbalanced ratios indicate integration. Its diagnostic and predictive performances were compared with those
of E2/E6E7 ratio analysis. The detection accuracy of both techniques was evaluated using the gold-standard technique
“detection of integrated papillomavirus sequences” (DIPS). To realize a multigenotypic detection goal, a primer and
probe library was established.
Results: The integration rate of a particular genotype of HPV was correlated with its tumorigenic potential and women
with higher lesion grades often carried lower viral loads. The E1-L1/E6E7 ratio analysis achieved 92.7% sensitivity and
99.0% specificity in detecting HPV integration, while the E2/E6E7 ratio analysis showed a much lower sensitivity (75.6%)
and a similar specificity (99.3%). Interference due to episomal copies was observed in both techniques, leading to
false-negative results. However, some positive results of E1-L1/E6E7 ratio analysis were missed by DIPS due to its
stochastic detection nature. The E1-L1/E6E7 ratio analysis is more efficient than E2/E6E7 ratio analysis and DIPS in
predicting precancerous/cancerous lesions, in which both positive predictive values (36.7%-82.3%) and negative
predictive values (75.9%-100%) were highest (based on the results of three rounds of biopsies).
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Conclusions: The multiple E1-L1/E6E7 ratio analysis is more sensitive and predictive than E2/E6E7 ratio analysis as
a triage test for detecting HPV integration. It can effectively narrow the range of candidates for colposcopic
examination and cervical biopsy, thereby lowering the expense of cervical cancer prevention.
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Cervical cancerBackground
Human papillomavirus (HPV) is a sexually transmitted
pathogen that has been linked to more than 90% of cer-
vical cancer events in women of childbearing age [1]. The
genome of this virus is composed of a covalently closed
circular DNA molecule, of which the viral gene compo-
nents are arranged in the order of DNA replication origin
(ori)-long control region (LCR)-E6-E7-E1-E2-E4-E5-L2-L1
(note: “E” refers to “early gene”; “L” refers to “late gene”;
see Figure 1A) [2]. The natural course for an initial HPV
infection to develop into a precancerous/cancerous lesion
in the uterine cervix usually takes a long period, even a
decade [3]. Persistent infection with HPV, therefore, is
regarded as a prerequisite to the generation of cervical
cancer [1-3]. Given these conditions, detection techniques
that can accurately diagnose persistent HPV infection when
there are no visible precancerous/cancerous changes in the
cervix are demanded by clinicians.
HPV genomic integration is a form of persistent viral
infection [4]. A series of large-scale population-based
epidemiological studies have demonstrated that integrated
HPV can persist much longer than can non-integratedFigure 1 Schematic representation of the primer design strategy and
analysis, six pairs of primers, corresponding to the gene regions E1, E2, E4E
of HPV. The products of each primer pair were 1–2 kb in length. Of these pair
All of the 12 component primers and their complementary sequences we
B. The numbers of DNA amplification reactions respectively required by eHPV (i.e., episomal HPV) [4-10]. In addition, epidemio-
logical investigations have reported that the integrated in-
fection rate reached 90%-100% in HPV-positive cervical
epithelium, which eventually develops into the canceration
stage [4-7]. The role of HPV integration in the infection-
persistence mechanism could be attributed, to a greater
degree, to the host cells losing their ability to discriminate
the pathogenic (i.e., HPV) DNA from their own and,
therefore, the ability of these cells to eliminate the
pathogenic DNA and, to a lesser degree, to the viral
DNA being covalently linked into host chromosomes
and being spared a fate of being diluted by cell division
[8]. However, viral integration impairs the genomic
stability of the host cells. Chromosomal abnormalities
are frequently found at virus insertion sites, and the neigh-
boring oncogenes or tumor suppressor genes could thus
be activated or repressed [9,10].
Previous in vitro experiments have confirmed that in
precancerous cervical epithelial cells that originally har-
bored only episomal HPV copies, the frequency of HPV
integration into the human genome increases with cell
division and with the canceration degree that these cellsrequired DNA amplification reactions. A. For the E1-L1/E6E7 ratio
5, L2, L1 and E6E7, were evenly arranged along the genome sequence
s, the E2 and E6E7 primer pairs were used for the E2/E6E7 ratio analysis.
re also used in the DIPS-PCR. (refer to Additional file 2: Figure S1).
ach detection technique are displayed.
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HPV DNA could be more effective than are traditional
methods that simply measure viral copies to assess the risk
of cervical cancer. However, so far, there are few detection
tools available for performing a routine examination for
integrated HPV infection in the clinical setting. Most of
the existing techniques for detecting HPV integration,
such as the “detection of integrated papillomavirus se-
quences (DIPS)” [12] and the “amplification of papilloma
virus oncogene transcripts (APOT)” [13], rely on a precise
DNA sequencing-based analysis and are extremely com-
plex in their operation protocols, making these techniques
both labor-intensive and time-consuming.
In this study, we developed a novel multiple E1-L1/E6E7
gene copy number ratio-based technique (henceforth re-
ferred to as “multiple E1-L1/E6E7 ratio analysis”) to detect
integrated HPV infection in the cervix. This technique is
derived from an already existing but less sensitive E2/E6E7
gene copy number ratio-based polymerase chain reaction
(PCR) technique (henceforth referred to as “E2/E6E7 ratio
analysis”) [14,15]. To improve its performance in discerning
the HPV physical status, we extended the original 1-kb
PCR-amplification region within the HPV E2 gene to a
6-kb region that contains viral genes from E1 through L1.
The principle of the copy number ratio-based technique is
that HPV integration often occurs within the E1-L1 gene
regions, especially the E2 region, and if the viral DNA dis-
ruption site occurs within these regions, the corresponding
PCR products should be diminished [15]. Our aim was to
determine whether the extended PCR detection region is
helpful to enhance the efficacy of the copy number ratio-
based method for detecting the integrated infection of HPV
and whether this novel technique can be used as a triage
test to screen for dangerous precancerous/cancerous cases
in women with a positive cervical HPV DNA test and
abnormal cytological examination findings.
Methods
Study population
From January 1, 2011 through December 31, 2012, cervical
cytological samples that were diagnosed with pathological
abnormalities (e.g., atypical squamous/glandular cells,
squamous intraepithelial lesions, etc., using the terminology
of the 2001 Bethesda system [16]) in Pap smear or liquid-
based cytological examinations (ThinPrep 2000, Hologic,
Bedford, Massachusetts, USA) were collected from patients
who accepted the colposcopy-based cervical biopsy in
Fengxian Hospital, Southern Medical University; Ob-
stetrics and Gynecology Hospital, Fudan University; and
Renji Hospital, Jiaotong University in Shanghai, China.
Informed consent forms were signed by all of the
enrolled women, and the biopsy samples were independ-
ently reviewed by two pathologists through hematoxylin
and eosin (H & E)-stained sections. As an inclusioncriterion, all of the women were required to persistently
test positive in their cervical HPV DNA tests (Multiple-
genotype HPV Fluorescent Quantitative PCR Detection
Kit, Fosun, Shanghai, China) for at least 6 months before
the biopsy. After the first biopsy, the women who had no
precancerous or cancerous changes found were requested
to repeat an cervical biopsy one month later, and if the bi-
opsy result was negative again, the women were required
to repeat the course for a third time. The women who had
three normal/cervicitis results were considered negative
cases. The research protocol was approved by the ethics
committee of Fengxian District Central Hospital.
HPV genotyping
For each patient, the total DNA was isolated from a 15-mL
cervical cytological sample (collected by cervical brushing)
using a QIAamp DNA Mini Kit (Qiagen, Shenzhen,
Guangdong, China) and maintained in phosphate-
buffered saline at −20°C). The quality of the DNA
samples was tested by measuring the β-actin (ACTB)
copies. An ACTB primer pair (Additional file 1: Table S1)
and a corresponding TaqMan probe (Additional file 1:
Table S1) were used. The synthesized ACTB DNA tem-
plate (note: all of the primers, probes and templates that
were used in this study were synthesized by Sangon,
Shanghai, China) was used to construct the standard curve
for the real-time PCR system. Only those samples contain-
ing the ACTB copy content greater than 1 × 10−8 μM
(equal to 103 cells/μL) were considered qualified samples.
The consensus HPV L1 primer pair MY09/11 was adopted
to amplify viral genomic DNA. The resultant PCR product
was hybridized with a panel of 45 HPV-genotypic probes on
a positively charged nylon membrane (GE, Piscataway,
New Jersey, USA) based on the method described by Oh
et al. [16]. The patients with a multigenotypic HPV infec-
tion were excluded from the study population.
HPV DNA load analysis
For each HPV genotype, a pair of E6E7-specific primers
(Additional file 1: Table S1) and a corresponding TaqMan
probe (Additional file 1: Table S1) were used. The synthe-
sized viral genotype-specific E6E7 DNA templates were
adjusted to 1 × 10−3 μM, and their 1/10 serial dilutions were
used to construct the standard curves for the real-time
PCR system. The mean E6E7/ACTB ratio was calculated
based on three replicates of E6E7 and ACTB quantitative
tests in each cervical sample. The viral DNA load was
represented as the per cell E6E7 copy number (note: each
human cell contains two copies of ACTB gene in general).
E2/E6E7 ratio analysis
Based on the viral genotyping results, the genotype-specific
E2 primer pairs and E6E7 primer pairs (Additional file 1:
Table S1) were used for the real-time PCR-based E2/E6E7
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E2 and E6E7 gene regions were used in the real-time PCR,
and their detailed sequences are listed in Additional file 1:
Table S1. For each viral genotype, the E2 and E6E7 DNA
templates were synthesized and adjusted to 1 × 10−3 μM;
1/10 serial dilutions of the two templates were used to
construct the standard curves. The E2/E6E7 ratio was
used to evaluate the physical status of HPV. The ratios
that were greater than 0.90, between 0.1 and 0.90, and
less than 0.1 were considered episomal, mixed and inte-
grated HPV infections, respectively.Multiple E1-L1/E6E7 ratio analysis
For the multiple E1-L1/E6E7 ratio analysis (Figure 1A), the
appropriate E1, E2, E4E5, L2 and L1 primer pairs, E6E7
primer pair and corresponding TaqMan probes were used
(Additional file 1: Table S1). The E1, E2, E4E5, L2, L1 and
E6E7 DNA templates were synthesized for each HPV
genotype and adjusted to 1 × 10−3 μM, and 1/10 serial
dilutions of these templates were used in the standard
curve constructions. To establish the viral physical sta-
tus, the E1/E6E7, E2/E6E7, E4E5/E6E7, L2/E6E7 and
L1/E6E7 ratios were divided into three classes. Class 1
included all of the ratios that were greater than 0.90,
indicating episomal HPV infection; Class 2 included the
ratios between 0.1 and 0.90, indicating mixed HPV
infection; and Class 3 included the ratios less than 0.1,
indicating integrated HPV infection.DIPS
The DIPS analysis was performed based on the methods
of Luft et al. [12] with necessary modifications for adapt-
ing different HPV genotypes. Briefly, the cellular genomic
DNA (0.6 mg) was digested with TaqI or Sau3AI (10 units,
New England Biolabs, Ipswich, Massachusetts, USA).
Enzyme-specific adapters were ligated to the digested
DNA using the T4-DNA ligase (10 units, New England
Biolabs). The obtained adapter-ligated DNA fragments
were amplified through a two-step PCR protocol. In the
initial PCR step, the DNA fragments were linearly amp-
lified using a single HPV genotype-specific viral primer,
and then in the second step, the obtained DNA product
was further exponentially amplified using a HPV genotype-
specific viral primer and an adapter-specific primer
(Additional file 1: Table S1). For each sample, the 12 HPV
genotype-specific viral primers and their reversely comple-
mentary counterparts were seriatim used in combination
with the adapter-specific primer to amplify the viral-
cellular junction-containing sequence (Figure 1A). The
PCR products that were obtained from any primer pair of
the above 24 combinations were sequenced to check the
viral-cellular junction. The Caski, SiHa, and HeLa cell
lines were used as positive controls.Statistical analysis
The two-sided Student’s t test was used to compare the
means of age, parity and gravidity between the enrolled
and pre-excluded women. A one-way ANOVA was used
to compare the means of viral DNA loads between women
with different grades of cervical lesions. The two-sided
χ2 test was used to compare categorical data, such as
differences in the cyto-pathological findings between the
enrolled and pre-excluded women, differences in the age-
related, genotype-related and cervical lesion-related distri-
bution patterns between integrated/mixed infection and
episomal HPV infection and differences in the numbers of
false-positive cases and false-negative cases as detected by
the E2/E6E7 ratio analysis or E1-L1/E6E7 ratio analysis
among the viral load tertiles. Pearson’s product–moment
correlation coefficient was used to estimate the relation-
ship between the integration rates and tumorigenic rates
of the 25 HPV genotypes. The κ value was used to esti-
mate the degree of consistency between the cases that were
diagnosed by the E2/E6E7 ratio analysis, E1-L1/E6E7 ratio
analysis and DIPS analysis. The SPSS 17.0 software package
(IBM, Armonk, New York, USA) was used, and p < 0.05
was defined as statistically significant.
Results
A total of 1162 women with single-genotypic HPV infec-
tions in the cervix were enrolled. All of the cervical bi-
opsies were performed due to abnormal findings in the
cervical cytological examinations (Table 1). The mean
age was 36.1 years (range: 21–68 years), and the age-
related distribution pattern is shown in Figure 2A. The
HPV L1 genotyping results revealed 25 viral genotypes,
namely, (from high to low in the order of case number)
HPV 16, 18, 33, 31, 39, 35, 6, 53, 56, 58, 68, 66, 52, 11,
51, 45, 59, 69, 62, 61, 42, 41, 26, 74 and 93. The corre-
sponding numbers (percentages) were 602 (51.8%), 126
(10.8%), 89 (7.7%), 79 (6.8%), 35 (3.0%), 29 (2.5%), 27
(2.3%), 26 (2.2%), 21 (1.8%), 19 (1.6%), 18 (1.5%), 16
(1.4%), 13 (1.1%), 9 (0.8%), 8 (0.7%), 8 (0.7%), 7 (0.6%),
7 (0.6%), 6 (0.5%), 5 (0.4%), 5 (0.4%), 3 (0.3%), 2 (0.2%),
1 (0.1%) and 1 (0.1%), respectively (Table 2). Women
with multi-genotypic HPV infections were pre-excluded;
the number of such women was 313, accounting for 21.2%
of all of the women (i.e., 1475 cases) that were screened
(Table 1).
A colposcopy-based biopsy was performed to evaluate
the pathological status of the cervix. To avoid missed bi-
opsies, patients with negative results underwent up to two
additional rounds of biopsies within three months. A total
of 514 precancerous/cancerous cases were thereby identi-
fied, including 286 cases of cervical intraepithelial neopla-
sia (CIN) I, 189 cases of CIN II, 36 cases of CIN III and 3
cases of invasive cancer. The first-round biopsy detected
477 (92.8%) cases; the second-round biopsy detected 26
Table 1 The clinicopathological characteristics of the









Age 36.1 ± 8.1 37.0 ± 7.8 0.066
Parity 2.2 ± 1.5 2.1 ± 1.2 0.118
Gravidity 0.6 ± 0.6 0.7 ± 0.7 0.346
Abnormal cervical cytological findings† 0.061
SCC 5 (0.4) 0 (0)
HSIL 256 (22.0) 76 (24.3)
LSIL 569 (49.0) 136 (43.5)
ASC-H 123 (10.6) 25 (8.0)
ASC-US 186 (16.9) 71 (22.7)
AIS 0 (0) 0 (0)
AGC-neoplastic 2 (0.2) 0 (0)
AGC-NOS 21 (1.8) 5 (1.6)
*The data are presented as mean ± standard deviation or number (%).
†SCC, squamous cell carcinoma; HSIL, high grade squamous intraepithelial
lesion; LSIL, low grade squamous intraepithelial lesion; ASC-H, atypical
squamous cells – cannot exclude HSIL; ASC-US, atypical squamous cells of
undetermined significance; AIS, adenocarcinoma in situ; AGC-neoplastic,
atypical glandular Cells, suspicious for AIS or cancer; AGC-NOS, atypical
glandular cells not otherwise specified.
‡Two-sided Student’s t test or two-sided χ2 test was used as appropriate.
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cases. The age-related distribution pattern of biopsy-
diagnosed precancerous/cancerous cases is shown in
Figure 2A. The number of precancerous/cancerous cases
peaked at the age of 35–39 years, while the number of
non-precancerous/cancerous cases peaked at the age of
30–34 years. A significant time retardation was observed
between the two peak age groups (p < 0.001, two-sided χ2
test, Figure 2A).
Based on the DIPS analysis, HPV integration events
(including the integrated and mixed HPV infection) were de-
tected in 312 (312/514, 60.7%) patients with precancerous/
cancerous lesions and in 45 (45/648, 6.9%) patients
without such lesions. The cervical lesion-related HPV
integration rates are shown in Figure 2B, and this difference
was of statistical significance (p < 0.001, two-sided χ2 test).
The age-related distribution patterns of the DIPS-confirmed
(i.e., integrated/mixed infection) and DIPS-denied (i.e.,
episomal infection) cases are shown in Figure 2A. A
similar time retardation was observed between the two
peak age groups with (i.e., integrated/mixed infection)
and without (i.e., episomal infection) HPV integration
events (Figure 2A). Relative to the precancerous (CIN
I-III)/cancerous cases that were detected by biopsies,
the sensitivity, specificity, and positive (PPV) and nega-
tive (NPV) predictive values of DIPS were 60.7%, 93.1%,
87.4% and 74.9%, respectively (Figure 3A). For higher
grades of lesions, that is, CIN II-III and invasive cancer,the DIPS sensitivity increased to 72.4%; when there were
only CIN III and invasive cancer, the sensitivity increased
to 100%; and when the lesions were restricted to invasive
cancer cases, the sensitivity was 100% (Figure 3A). Never-
theless, the specificity and PPV of DIPS decreased as the
CIN grades increased, especially the latter, which even de-
creased to 10.9% and 0.8% for lesions higher than CIN III
and invasive cancer cases, respectively (Figure 3A). On the
other hand, the NPVs were slightly increased as the lesion
grades increased, which were 92.2% for the lesions that
were equal to/higher than CIN II, 100% for the lesions that
were equal to/higher than CIN III and 100% for the inva-
sive cancer cases, displaying a similar pattern as that of
the sensitivity (Figure 3A). Regarding the viral genotype-
related distribution, HPV 16 and 18 gave rise to a major
part of the integrated/mixed infection cases that we de-
tected, namely, 46.5% and 14.8%, respectively (Table 2).
The viral integration rates (IRs, i.e., the percentage of HPV
integration cases in the women that were infected with a
certain genotype of HPV), however, from the highest to
the lowest, were HPV 45 (IR = 62.5%), 26 (IR = 50%), 18
(IR = 42.1%), 31 (IR = 41.8%), 33 (IR = 40.4%), 39 (IR =
40.0%), 52 (IR = 38.5%), 51 (IR = 37.5%), 35 (IR = 34.5%),
69 (IR = 28.6%), 68 (IR = 27.8%), 16 (IR = 27.7%), 53 (IR =
26.9%), 66 (IR = 25.0%), 56 (IR = 23.8%), 42 (IR = 20.0%),
61 (IR = 20.0%), 62 (IR = 16.7%), 58 (IR = 15.8%), 59 (IR =
14.3%) and 6 (IR = 3.7%) (Table 2 and Additional file 2:
Figure S2). No integration events were found in the HPV
11-, 41-, 74- and 93-positive cases (Table 2). For all of the
HPV genotypes, the tumorigenic rates (TRs, i.e., the per-
centage of CIN or invasive cancer cases in the women that
were infected with a given genotype of HPV) were posi-
tively correlated with their IRs in the study population
(Figure 2C).
Table 3 lists the detection results of two copy number
ratio-based techniques. The viral integration events that
were identified by the E1-L1/E6E7 ratio analysis were
fewer by 18 cases than those identified by DIPS and were
more by 63 cases than those identified by the E2/E6E7 ratio
analysis (for details, see Additional file 1: Tables S2-S30).
When considering DIPS as a gold-standard technique,
there were 8 cases that were false-positively diagnosed
by the E1-L1/E6E7 ratio analysis and 26 cases that were
false-negatively diagnosed (Table 3). No cases that were
identified by the E2/E6E7 ratio analysis were missed by
the E1-L1/E6E7 ratio analysis (Additional file 1: Table S5).
Relative to the E2/E6E7 ratio analysis, of the 63 cases that
were additionally detected by the E1-L1/E6E7 ratio ana-
lysis, 96.8% (61/63) were confirmed by DIPS (Table 3).
Moreover, for the 61 DIPS-confirmed cases, the viral-
cellular junction sequencing results indicated that the viral
disruption points were all located outside the E2 region
(Additional file 1: Tables S2-S30 and in Additional file 2:
Figure S1). Relative to DIPS, the multiple E1-L1/E6E7
Figure 2 The relationship between cervical lesions and HPV integration. A. The age-related distribution patterns of cervical lesions (upper panel)
and HPV integration events (lower panel, detected with DIPS) in the enrolled women. A significant time retardation was observed between women
with cervical precancerous/cancerous lesions and those without lesions as well as between women with cervical integrated/mixed HPV infections and
those with episomal infections. B. The cervical lesion-related distribution pattern of HPV integration is displayed. C. The relationship between the HPV
integration rate and its tumorigenic rates was analyzed using the Pearson’s product–moment correlation coefficient, r. Blue line, the linear fitting curve.
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and 99.0% in detecting HPV integration (integrated/mixed
HPV infection) events, respectively, whereas the E2/E6E7
ratio analysis exhibited a sensitivity and specificity of 75.6%
and 99.3%, respectively (Table 3). To diagnose cervical pre-
cancerous/cancerous lesions, the E1-L1/E6E7 ratio analysis
exhibited a sensitivity, specificity, PPV and NPV of 60.9%,
96.0%, 92.3% and 75.6%, respectively, and the E2/E6E7
ratio analysis exhibited a sensitivity, specificity, PPV and
NPV of 51.9%, 98.6%, 95.7% and 72.1%, respectively
(Figure 3A). As the lesion grades increased, the diag-
nostic performance of the two copy number ratio ana-
lyses followed a similar pattern as that of the DIPS,
except that the E2/E6E7 ratio analysis showed obvious
deficiencies in its detection sensitivity for cervical le-
sions that were higher than CIN III and invasive cancer
(Figure 3A).With respect to the detection consistencies,
the κ coefficient was 0.80 between the E2/E6E7 ratio andDIPS analyses (with 93 cases of difference), 0.93 between
the multiple E1-L1/E6E7 ratio and DIPS analyses (with 34
cases of difference), and 0.86 between the two copy num-
ber ratio-based techniques (with 63 cases of difference)
(Figure 3B and Additional file 1: Tables S3-S5). Meanwhile,
the age-, cervical lesion- and HPV genotype-related distri-
bution patterns of the HPV integration events that were
detected by copy number ratio techniques showed no
significant differences from those of the DIPS analysis
(Additional file 2: Figure S2).
To confirm whether the viral load affects the detection
consistency between the copy number ratio-based tech-
niques and DIPS, we divided HPV-infected cases into
tertiles based on the E6E7/ACTB ratios. In the highest
(first) tertile, relative to the results of DIPS, both the
numbers and percentages of false-negative cases in the
two copy number ratio-based analyses peaked (38 and
55.1% for the E2/E6E7 ratio analysis and 17 and 24.6%
Table 2 The age-related distributional characteristics and physical statuses of the 25 HPV genotypes detected*
HPV
genotypes

























HPV 6 2 (3.0) 4 (1.9) 12 (4.6) 2 (0.9) 2 (0.9) 4 (3.3) 0 (0) 0 (0) 0 (0) 1 (50.0) 25 (3.1) 2 (0.6)
HPV 11 2 (3.0) 2 (1.0) 2 (0.8) 3 (1.3) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 9 (1.1) 0 (0)
HPV 16 20 (30.3) 126 (60.9) 136 (51.9) 113 (48.1) 117 (55.2) 64 (52.9) 18 (43.9) 4 (36.4) 3 (60.0) 1 (50.0) 436 (54.2) 166 (46.5)
HPV 18 9 (13.6) 12 (5.8) 16 (6.1) 36 (15.3) 25 (11.8) 21 (17.4) 5 (12.2) 1 (9.1) 1 (9.1) 0 (0) 73 (9.1) 53 (14.8)
HPV 26 0 (0) 0 (0) 1 (0.4) 0 (0) 0 (0) 1 (0.8) 0 (0) 0 (0) 0 (0) 0 (0) 1 (0.1) 1 (0.3)
HPV 31 5 (7.6) 7 (3.4) 17 (6.5) 22 (9.4) 19 (9.0) 3 (2.5) 5 (12.2) 1 (9.1) 0 (0) 0 (0) 44 (5.5) 35 (9.8)
HPV 33 9 (13.6) 11 (5.3) 21 (8.0) 16 (6.8) 20 (9.4) 7 (5.8) 3 (7.3) 1 (9.1) 1 (20.0) 0 (0) 53 (6.6) 36 (10.1)
HPV 35 1 (1.5) 3 (1.4) 9 (3.4) 8 (3.4) 3 (1.4) 2 (1.7) 2 (4.9) 1 (9.1) 0 (0) 0 (0) 19 (2.4) 10 (2.8)
HPV 39 1 (1.5) 5 (1.5) 13 (2.4) 7 (5.0) 4 (3.0) 2 (1.9) 2 (1.7) 1 (4.9) 0 (0) 0 (0) 21 (2.6) 14 (3.9)
HPV 41 0 (0) 1 (0.5) 1 (0.4) 0 (0) 0 (0) 1 (0.8) 0 (0) 0 (0) 0 (0) 0 (0) 3 (0.4) 0 (0)
HPV 42 2 (3.0) 1 (0.5) 0 (0) 0 (0) 0 (0) 2 (1.7) 0 (0) 0 (0) 0 (0) 0 (0) 4 (0.5) 1 (0.3)
HPV 45 1 (1.5) 1 (0.5) 1 (0.4) 0 (0) 1 (0.5) 2 (1.7) 1 (2.4) 1 (9.1) 0 (0) 0 (0) 4 (0.5) 4 (1.1)
HPV 51 1 (1.5) 2 (1.0) 3 (1.1) 1 (0.4) 1 (0.5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 5 (0.6) 3 (0.8)
HPV 52 2 (3.0) 3 (3.0) 3 (1.4) 3 (1.1) 2 (1.3) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 8 (1.0) 5 (1.4)
HPV 53 3 (4.5) 4 (1.9) 9 (3.4) 3 (1.3) 2 (0.9) 2 (1.7) 2 (4.9) 1 (9.1) 0 (0) 0 (0) 20 (2.5) 6 (1.7)
HPV 56 1 (1.5) 5 (0.4) 4 (1.5) 4 (1.7) 3 (1.4) 3 (2.5) 1 (2.4) 0 (0) 0 (0) 0 (0) 16 (2.0) 5 (1.4)
HPV 58 2 (3.0) 4 (1.9) 3 (1.1) 5 (2.1) 2 (0.9) 3 (2.5) 0 (0) 0 (0) 0 (0) 0 (0) 16 (2.0) 3 (0.8)
HPV 59 1 (1.5) 2 (1.0) 2 (0.8) 1 (0.4) 1 (0.5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 6 (0.7) 1 (0.3)
HPV 61 0 (0) 1 (0.5) 1 (0.4) 2 (0.9) 0 (0) 1 (0.8) 0 (0) 0 (0) 0 (0) 0 (0) 4 (0.5) 1 (0.3)
HPV 62 0 (0) 2 (1.0) 1 (0.4) 2 (0.9) 1 (0.5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 5 (0.6) 1 (0.3)
HPV 66 2 (3.0) 6 (2.9) 2 (0.8) 3 (1.3) 3 (1.4) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 12 (1.5) 4 (1.1)
HPV 68 1 (1.5) 3 (1.4) 3 (1.1) 2 (0.9) 5 (2.4) 2 (1.7) 2 (4.9) 0 (0) 0 (0) 0 (0) 14 (1.7) 4 (1.1)
HPV 69 0 (0) 2 (1.0) 1 (0.4) 2 (0.9) 1 (0.5) 1 (0.8) 0 (0) 0 (0) 0 (0) 0 (0) 5 (0.6) 2 (0.6)
HPV 74 1 (1.5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (0.1) 0 (0)
HPV 93 0 (0) 0 (0) 1 (0.4) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (0.1) 0 (0)
*The data are presented as numbers (%).
†No significant differences found in the age-related distribution patterns of the 25 HPV genotypes, χ2 = 217.4, p = 0.461, two-sided χ2 test.
‡Significant difference found between the episomal and integrated/mixed infection rates of the 25 HPV genotypes, χ2 = 47.3, p = 0.003, two-sided χ2 test.
§DIPS cannot differentiate the mixed HPV infection cases from the integrated infection cases.
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Additionally, there were 2 (0.6%) and 2 (0.6%) false-positive
cases raised by the copy number ratio-based analyses in this
tertile, respectively (Table 3 and Figure 3D). In the middle
(second) and lowest (third) tertiles, the numbers and
percentages of false-negative cases decreased in both of the
copy number ratio-based analyses (Table 3 and Figure 3D);
however, false-positive cases still existed, and even in the
E1-L1/E6E7 ratio analysis the number and percentage
of false-positive cases increased by approximately 2-fold
compared to those that were observed in the first tertile
(Table 3). Most of the false-negative cases that were
caused by the copy number ratio-based techniques oc-
curred in patients with no precancerous/cancerous changes
or low-grade CIN (CIN I), but the false-positive cases were
more frequently observed in patients with higher grades
of CINs (CIN II and III) and invasive cancer (Figure 3D).Correspondingly, the number of CIN and cervical cancer
cases showed tended to occur at lower viral load tertiles,
but normal cervix/cervicitis cases more often appeared
in the first and second tertiles (p < 0.001, ANOVA,
Additional file 2: Figure S3). The observed viral load
difference between the cervical lesion groups (normal/
cervicitis, CIN I-III, invasive cancer) was of statistical
significance (p < 0.001, ANOVA, Figure 3C).
Because our purpose for detecting integrated HPV in-
fection in the cervix was to promote the early diagnosis
(i.e., as a triage test) of cervical precancerous/cancerous
lesions, we compared the efficacies of the three techniques,
namely, DIPS, E2/E6E7 ratio analysis and multiple E1-L1/
E6E7 ratio analysis, in predicting CIN or invasive cancer
cases among the enrolled women. As shown in Figure 3E,
the PPVs of the three techniques for CINs were 78.2%
(DIPS), 84.1% (E2/E6E7) and 82.3% (E1-L1/E6E7) during
Figure 3 The diagnostic performance of the copy number ratio-based techniques and DIPS. A. Diagnostic performance of the three
techniques, i.e., DIPS, the E2/E6E7 ratio analysis and the E1-L1/E6E7 ratio analysis, on the different grades of cervical precancerous/cancerous
lesions. Ca, invasive cancer. B. Schematic representation of the detection ranges of the two copy-number-based techniques and DIPS and their
relationships with the population of cervical lesions. C. Box plots indicating the viral load distribution characteristics among women with different
levels of cervical lesions. D. The distribution characteristics of false-positive cases and false-negative cases that were detected by the E2/E6E7 ratio
analysis and the E1-L1/E6E7 ratio analysis are shown, together with their corresponding viral loads. * and #, The differences between the numbers of
false-negative cases between the five grades of cervical lesions were of statistical significance, p < 0.001, two-sided χ2 test. ** and ##, The differences
between the numbers of false-negative cases between three viral load tertiles were of statistical significance, p < 0.001, two-sided χ2 test. Ca, invasive
cancer. E. Predictive performance of the three techniques on the cervical precancerous/cancerous lesions during the three rounds of cervical biopsies.
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namely, 75.4% (DIPS), 72.3% (E2/E6E7) and 75.9% (E1-L1/
E6E7), respectively. During the second-round biopsy, the
PPVs of the three techniques decreased to 30.8% (DIPS),
36.4% (E2/E6E7) and 45.5% (E1-L1/E6E7), respectively,
while their NPVs all increased, namely, 99.7% (DIPS),
99.1% (E2/E6E7) and 100% (E1-L1/E6E7), respectively. For
the third-round biopsy, the PPV of DIPS decreased to
16.7%, while the PPVs of the two copy number ratio-based
analyses were 20.8% (E2/E6E7) and 36.7% (E1-L1/E6E7),respectively. However, the NPVs of the three techniques
were maintained stable at 99.7% (DIPS), 99.1% (E2/E6E7)
and 100% (E1-L1/E6E7), respectively. Although DIPS could
detect more cases of integrated HPV infection than could
the copy number ratio-based analyses, our results indicate
that this performance was not necessarily associated with
the ability to predict cervical precancerous/cancerous
lesions. Indeed, the E2/E6E7 ratio analysis and E1-L1/
E6E7 ratio analysis, which exhibited moderate and lower
sensitivities for HPV integration events, respectively, both
Table 3 The diagnostic efficacies of the E2/E6E7 and multiple E1-L1/E6E7 ratio analyses in relation to DIPS
DIPS
E2/E6E7 ratio analysis* E2-L1/E6E7 ratio analysis*
Positive† Negative‡ Positive† Negative‡
All women (1162 cases)
positive (n = 357) 270 (75.6) 87 (24.4) 331 (92.7) 26 (7.3)
negative (n = 805) 6 (0.7) 799 (99.3) 8 (1.0) 797 (99.0)
Women in the highest tertile (387 cases, viral DNA load ≥ 36.7 copies/cell)§
positive (n = 69) 31 (44.9) 38 (55.1) 52 (75.4) 17 (24.6)
negative (n = 318) 2 (0.6) 316 (99.4) 2 (0.6) 316 (99.4)
Women in the middle tertile (387 cases, 12.7 copies/cell ≤ viral DNA load < 36.7 copies/cell)§
Positive (n = 123) 97 (78.9) 26 (21.1) 118 (95.9) 5 (4.1)
negative (n = 264) 2 (0.8) 262 (99.2) 2 (0.8) 262 (99.2)
Women in the lowest tertile (388 cases, viral DNA load <12.7 copies/cell)§
positive (n = 165) 142 (86.1) 23 (13.9) 161 (97.6) 4 (2.4)
negative (n = 223) 2 (0.9) 221 (99.1) 4 (1.8) 219 (98.2)
*The data are presented as numbers (%).
†The positive cases include both the mixed and integrated HPV infection cases that were detected by the copy number ratio-based techniques.
‡The negative cases indicate the episomal HPV infection cases that were detected by the copy number ratio-based techniques.
§The women were divided into tertiles according to their viral DNA loads as determined by real-time PCR in the cervical samples.
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rounds of biopsies. The E1-L1/E6E7 ratio analysis especially
exhibited the supreme PPVs and NPVs before the second-
and third-round biopsies, indicating its excellent value in
directing repeated biopsies in the suspected women.
We examined the detection reproducibility of the three
techniques one month after a first-round test. Following
two additional rounds of analyses on the remaining cer-
vical samples preserved at −20°C, the coefficients of
variation (CVs) of each copy number ratio analysis were
obtained, which were 5.1%-7.8% (E1/E6E7), 3.9%-5.6%
(E2/E6E7, for both the E2/E6E7 ratio- and E1-L1 ratio-
based techniques), 2.3%-6.9% (E4E5/E6E7), 2.9%-8.2%
(L2/E6E7) and 3.1%-7.1% (L1/E6E7), respectively. Using
CV = 10% as a threshold, the quantification stability of the
two techniques was acceptable. Moreover, the detection
consistency (i.e., reproducibility) of the three rounds of
tests was 100% for both of the techniques. However, 79
(79/357, 22.1%) of the integrated/mixed infection cases
that were identified during the first-round DIPS failed to
be detected again during the second- or third-round
DIPS. Meanwhile, two of the so-called false-positive
cases (Patient Nos. 179275 and 624287, Additional file 1:
Tables S8 and S25) as detected by the copy number ratio-
based techniques were proven to be true positives by the
second-round DIPS (but it failed again in the third-round
detection). In total, three cases were thus corrected by a
second- or third-round DIPS (Table 4 and Additional file 1:
Tables S8, S12 and S25). Therefore, the detection re-
producibility of this technique was 92.9% (1080/1162).
In addition, we re-examined the remaining five cases
that were denied by DIPS but positively diagnosed by
E2/E6E7 ratio analysis or E1-L1/E6E7 ratio analysis usinga modified version of DIPS in which the endonucleases
TaqI and Sau3AI were substituted with Csp6I. As a re-
sult, another case (Patient No. 189543, Additional file 1:
Table S9) was confirmed as a true positive. The DNA se-
quencing results indicate there were no TaqI or Sau3AI
recognition sites within the 2–3 kb region franking the
viral-cellular junction of this case (Additional file 2:
Figure S1).
Discussion
Herein, we offered the first insight into a novel, practic-
able and multigenotype-oriented tool for detecting HPV
integration that was developed based on an existing, single-
genotypic, research-based technique, i.e., the E2/E6E7 ratio
analysis. In the population of enrolled women, this novel
technique has not only manifested a similar perform-
ance to that of DIPS, a recognized gold-standard detection
technique (Figure 3A), but also featured a simplified
process of operation, producing a workload that is about
one fourth that of DIPS (note: we assumed that the work-
load is proportional to the number of PCR reactions
required to perform a HPV integration test, while the
workload generated by DIPS via sample pretreatment
and PCR product sequencing has not been taken into
account) (Figure 1B).
In this study, the E1-L1/E6E7 ratio-based technique was
used to evaluate a total of 25 HPV genotypes (compared
to the E2/E6E7 ratio analysis and DIPS) for their physical
statuses. The number of HPV genotypes that were evalu-
ated, to the best of our knowledge, has reached the max-
imum among known studies concerning integrated HPV
infection. In previous studies, only two to five genotypes
of HPVs have been evaluated via three major techniques,
Table 4 The reproducibility of DIPS for triplicate testing of cytological samples after a one-month preservation*
DIPS rounds First-round DIPS (+)(n = 357)
First-round DIPS (−) (n = 805)
E2/E6E7 ratio analysis (+) &
E1-L1/E6E7 ratio analysis (+)
(n = 6)
E2/E6E7 ratio analysis (−) &
E1-L1/E6E7 ratio analysis (+)
(n = 2)
E2/E6E7 ratio analysis (−) &
E1-L1/E6E7 ratio analysis (−)
(n = 797)
Second-round
Confirmed: 299 Confirmed: 5 Confirmed: 2 Confirmed: 797
Denied: 58 Denied: 1 Denied: 0 Denied: 0
Reproducibility between 1st- and 2nd-round DIPS: 94.9%
Third-round
Confirmed: 281 Confirmed: 5 Confirmed: 1 Confirmed: 797
Denied: 76 Denied: 1 Denied: 1 Denied: 0
Reproducibility between 1st- and 3rd-round DIPS: 93.3%
Second- and
Third-round
Consistently confirmed: 278 Consistently confirmed: 4 Consistently confirmed: 1 Consistently confirmed: 797
General reproducibility: 92.9%
*The reproducibility was calculated by dividing the number of cases that were confirmed by two or three rounds of DIPS by the total number (n = 1162) of tested cases.
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However, such a narrow genotype range does not sat-
isfy the clinical demands, which could be associated with a
high misdiagnosis rate in women that are infected with
other HPV genotypes. In a nine-country collaborative inter-
national study, Muñoz et al. detected 30 genotypes among
the 1998 cases of cervical HPV-infected women (including
1739 cervical cancer and 259 simple infection cases) [17].
Similarly, in this study, we detected 25 genotypes in the
enrolled 1162 HPV-positive women, 19 of which were in
accordance with those that were reported by Muñoz et al.,
while the remaining six (HPV 41,61, 62, 69, 74 and 93)
were peculiar to the enrolled population, reflecting a
characteristic genotypic spectrum in Chinese women [17].
Together with the findings of Muñoz et al., our results sug-
gest that only the techniques that are applicable to 20 to 30
HPV genotypes can meet the practical need. We, there-
fore, built the primer and probe library (Additional file 1:
Table S1) to implement this aim, which can be extended
to additional HPV genotypes under necessary conditions.
This library comprises a common base in which to com-
pare the two copy number ratio-based techniques as well
as the standard technique DIPS in multigenotypic HPV.
It is noteworthy that we only adopted the primer and
probe library but not the traditional degenerate (i.e.,
consensus) primer strategy for adapting the three tech-
niques, i.e., DIPS, the E2/E6E7 ratio analysis and the
E1-L1/E6E7 ratio analysis, to detect multigenotypic
HPV [18-21]. Moreover, we used the sequence-specific
TaqMan probe but not DNA dyes, such as SYBR Green,
BEBO, SYTO, etc. [22], to determine the gene copy
number. Although degenerate primers have been widely
accepted by previous HPV detection tools, and the addition
of DNA dyes is a popular choice for lowering the expense
of a real-time PCR test, the quantification bias could be
inevitably induced by the mis-binding of these degenerate
primers to unexpected cellular/viral genomic sequences
and the insertion of DNA dyes to non-specific primerdimers and/or mistakenly amplified products [18-22].
Therefore, the adoption of sequence-specific primers
and probes could solve these problems. In addition,
Depuydt et al. reported that the L1 degenerate primer
pair MY09/11 varies in its ability to bind to L1 sequences
of different HPV genotypes, leading to a reduced sensitiv-
ity for several HPV genotypes [23]. This observation
further demonstrates the necessity of adopting genotype-
specific primers and probes in the multigenotypic detec-
tion system. Meanwhile, to avoid systemic bias between
techniques, the primers and probes that were designed
to recognize a given viral sequence target were identical
in all three techniques (Figure 1A and Additional file 1:
Table S1). These measures allow the results that were
obtained from each technique to be compared in a
homogenous technological background.
Based on the three compared techniques, i.e., the DIPS
analysis and the two copy number ratio-based analyses,
the importance of applying HPV integration tests as tools
to prevent cervical cancer was consistently demonstrated
by a panel of mutually corroborative lesion-, genotype-
and age-related distributional characteristics of integrated/
mixed HPV infections in the enrolled women. Our re-
sults indicate that, with increasing lesion grades, the
percentages of integrated/mixed infection cases increased
gradually (Figure 2B). This finding agrees with previous
epidemiological studies, which revealed similar patterns of
integration events in HPV 16-, 18-, 31-, 33-, 45-, 52- or 58-
infected women [7,24-26]. Nevertheless, our results have
generalized this ad hoc rule from one that was only valid
for a few HPV genotypes to a more common form that is
suitable for 25 or more HPV genotypes (Figure 2B and
Additional file 2: Figure S2). Meanwhile, based on the same
database, we are now able to unveil another epidemio-
logical rule, that is, the integration ability of a given HPV
genotype is positively correlated with its tumorigenic po-
tential (Figure 2C). This assertion can be seen as a direct
inference of the prior rule of the relationship between the
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specific to the oncological behavior of each HPV geno-
type. Frequent integration events can result in the early
occurrence of cervical cancer. In a study conducted by
Vinokurova et al., the integration rates of HPV 16, 18,
31, 33, and 45 were inversely correlated with the ages of
onset of cervical cancer [26]. Unfortunately, due to the
limited number of cancer cases (i.e., 3 cases) in this study,
we cannot confirm this finding in our population,
although a larger number of viral genotypes were
involved. However, we did observe an overlap of the peak
age groups of women with precancerous/cancerous lesions
and those with integrated/mixed HPV infections, which
has been confirmed by DIPS, the E2/E6E7 ratio analysis
and the E1-L1/E6E7 ratio analysis (Figure 2A). Addition-
ally, a time interval was observed between the peak age
groups of women with precancerous/cancerous lesions
and those of unaffected women and another similar inter
was found between the peak age groups of episomal- and
integrated/mixed-infection cases, indicating that HPV in-
tegration and cervical carcinogenesis develop in a syn-
chronous manner (Figure 2A). These lines of evidence
further demonstrate the necessity of adopting an HPV
integration test as a triage method to identify high-risk
women and provide them timely treatment and/or
intensive follow-up. These women were fundamental
for our comparison of the two copy number ratio-
based techniques.
Multigenotypic DIPS - a common reference platform
was established in our study for comparing the respect-
ive diagnostic accuracies of the E2/E6E7 ratio analysis and
the E1-L1/E6E7 ratio analysis in the enrolled women. The
original version of DIPS was designed for two genotypes
of HPVs, namely, HPV 16 and 18 [12]. The operating
principle of DIPS is to sequence the viral-cellular junction
in the integrated/mixed HPV-infected cells and, therefore,
to provide objective evidence for viral integration events
[12]. Theoretically, this method can exhaustively deter-
mine any possible insertion points of viral DNA in the
cellular genome. Therefore, in many previous studies,
DIPS has been treated as a gold-standard technique, es-
pecially for evaluating the diagnostic correctness of the
E2/E6E7 ratio analysis [5,7,14,15,24,25,27,28]. In this study,
DIPS unsurprisingly detected 18 and 81 additional cases
compared to those that were identified by the E2/E6E7
ratio analysis and the E1-L1/E6E7 ratio analysis, accounting
for 5% (18/357) and 22.7% (81/357) of the total integrated/
mixed infection cases, respectively (Table 3). Considering
the κ value as a measurement for evaluating technological
similarity, we observed that the technological characteristic
of the E1-L1/E6E7 ratio analysis is more similar to that
of DIPS but not to that of its prototype technique the
E2/E6E7 ratio analysis (Additional file 1: Tables S3-S5).
This result can be considered a major advantage of thecopy number ratio-based techniques following the exten-
sion of the originally limited detection region to a whole
viral genome in detecting HPV integrated/mixed infection.
Previously, using the whole-genome sequencing tech-
nique, Wang et al. found that there could be 67-81% in-
tegration events occurring outside the E2 gene region [29].
Our study supports their findings and demonstrates that
the non-E2 integration events represent a frequently
encountered phenomenon in the clinic, which could be
at least 17.1% (61/357) of the total integrated/mixed
infection cases. These integration events were also as-
sociated with a rate of precancerous/cancerous lesions
and, therefore, gave rise to a non-negligible group of high-
risk women (Figure 3D, Additional file 1: Tables S6-S30).
As such, the E1-L1/E6E7 ratio analysis is superior to the
E2/E6E7 ratio analysis as a triage test to screen for non-E2
HPV integration cases.
In the detection of integrated/mixed HPV infection, the
two copy number ratio-based techniques were being con-
fronted with the same problem: the complete viral genome
of episomal HPV copies can cover up a few viral sequence
deletions that are caused by the integration events, leading
to an indifferent copy number ratio to that of episomal in-
fection and, thereafter, to false-negative cases [30,31]. In
this study, we used DIPS to assess the influence of epi-
somal viral copies on the diagnostic correctness of the two
copy number ratio-based techniques. As a result, of the
357 integrated/mixed infection cases that were identified
by DIPS, 26 (7.3%) were not detected by either of the two
compared techniques (Table 3), indicating a systemic error
caused by the covering-up phenomenon in a background
of excessive episomal DNA. To confirm this hypothesis,
we analyzed the relationship between the viral DNA load
and the false-negative rate of the copy number ratio-based
analyses (Table 3, Figure 3D). The obtained results indi-
cate a positive correlation between the amount of epi-
somal viral DNA and the number of false-negative cases
that were detected by the E2/E6E7 ratio analysis or the
E1-L1/E6E7 ratio analysis, whereby the interference effect
of the episomal copies could be ascertained (note: most of
the cases in the highest tertile were denied by DIPS; there-
fore, they were at an episomal infection status) (Table 3,
Figure 3D). Given this result, it seems that the copy
number ratio-based techniques, regardless of form, cannot
bypass an inherent technical deficiency of this type. How-
ever, if considered in an opposite way, our result may be
interpreted as the copy number ratio-based techniques
should be preferentially used to detect HPV integration
events among women with lower viral DNA loads, thereby
reducing its false-negative rate. In fact, previous studies
have demonstrated that the viral integration process is
often accompanied by the lowering of the viral DNA load
as well as the increasing of the cervical lesion grade
[7,24-26,32-34]. The reason for this phenomenon could be
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ruption of the viral genome replication-related genes, such
as E1 and E2, or the activation of viral oncogenes E6 and
E7 after the integration event [35,36]. Here, our study sup-
portively confirms that lower viral load tertiles are associ-
ated with more integration events and higher incidence
rates of precancerous/cancerous lesions (Figure 3C and
Additional file 2: Figure S3). Therefore, the cases that were
identified by the copy number ratio-based techniques were
generally more severe in their pathological conditions
compared to those that were detected by DIPS because
most of these cases had lowered viral loads and were
near to the canceration stage (also see the analyses in
the following paragraphs) (Figure 3D). In addition, our
study demonstrates that the peak age group of integrated/
mixed HPV infection emerged approximately five years
after the peak age group of episomal HPV infection
(Figure 2A). Therefore, it is reasonable to use the long-
term (e.g., >six months) HPV-infected women as the tar-
get population of the copy number ratio-based methods.
This measure can be helpful to reduce the interference ef-
fect of episomal copies and improve the detection accur-
acy of the two copy number ratio-based techniques.
The enrolled population of this study consisted of women
with HPV infection > six months who had positive findings
in their cervical cytological examinations. Previous studies
indicated that 30%-60% of these women would be eventu-
ally diagnosed as normal or cervicitis cases [37,38]. There-
fore, colposcopy and cervical biopsy are not so necessary, at
least for some of the women, and can induce unnecessary
stress. In this study, we first tested the triage role of the
gold-standard technique, DIPS. For high-grade lesions
and invasive cancer, DIPS displayed satisfactory sensitivity:
66.7% (CIN II), 100% (CIN III) and 100% (invasive cancer)
(Figure 2B); the DIPS specificity was 93.1% for all of the
cases with no precancerous/cancerous lesions. However,
for the CIN I cases, the DIPS sensitivity was only 51.4%;
moreover, DIPS detected 45 (6.9%) integrated/mixed in-
fection cases in normal/cervicitis cases (Figure 2B). The
latter two phenomena comprise a major reason for erro-
neous diagnosis/prediction by DIPS in triaging cervical le-
sion cases (Figure 3A). Regarding the performances of the
two copy number ratio-based analyses, the E1-L1/E6E7 ra-
tio analysis exhibited sensitivity identical to that of DIPS
(60.9% vs. 60.7%) for all grades of precancerous/cancerous
lesion cases; the sensitivities of both the E1-L1/E6E7 ratio
analysis and DIPS were superior to that (51.9%) of the E2/
E6E7 ratio analysis. Nevertheless, regarding specificity,
PPV and NPV, the two copy number ratio-based tech-
niques exhibited similar performances to those of DIPS
(Figure 3A). Inevitably, no matter which technique is
performed, a proportion of lower grade (CIN I and II)
lesion cases or non-precancerous/cancerous lesion cases
will be misdiagnosed. Previous studies indicated that notall CIN cases occur due to HPV integration; conversely,
not all integration events result in precancerous/cancerous
lesions [7-9,24-28]. Moreover, integrated HPV requires a
period of time to exert its oncological function and induce
canceration of the affected cells [2,3,11]. Therefore, it is
reasonable to conclude that no HPV integration detection
technique can achieve 100% sensitivity or specificity in
precancerous/cancerous cervical lesions, especially for CIN
I and II cases. However, because it is more difficult to
eradicate integrated HPV DNA from the cellular genome,
CINs with integrated/mixed infections could be disposed
to persist or progress their conditions, while CINs with epi-
somal HPV infections can regress spontaneously [39,40].
Therefore, more attention should be paid to women with
integrated/mixed HPV infections, regardless of the grade
of their cervical lesions. To explain the difference in
sensitivity between the two copy number ratio-based
techniques, we refer to the detection bias between re-
strictive integration tests and systemic integration tests. A
restrictive integration test (i.e., that detects DNA fragments
of a partial viral genome), such as APOT (a technique that
detects the viral-cellular junction within the transcripts of
the E6E7 oncogene) and the E2/E6E7 ratio analysis, cannot
effectively examine all existing integrated/mixed infections
[6,12-15,26]. For example, Vinokurova et al. detected the
integration events in only 14%-92% of cervical cancer
patients using APOT [26], and Arias-Pulido et al. gained
an integration rate of 57.7%-65% in HPV 16-infected
women suffering from cervical cancer using an E2/E6E7
ratio-based technique [14]. In contrast, using DIPS, a sys-
temic integration test (i.e., detecting DNA fragments of
the whole viral genome), Luft et al. demonstrated that the
integration rate of HPV was close to or approached 100%
in HPV 16- and 18-infected patients with cervical cancer
[12]. These findings indicate that only a systemic integra-
tion test could reach 100% sensitivity in predicting cervical
cancer cases. Our study, therefore, confirmed another sys-
temic integration test, the E1-L1/E6E7 ratio analysis, as
capable of sensitively identifying the women with high-risk
cervical precancerous/cancerous lesions based on a wider
range of HPV genotypes and that is more eligible than the
E2/E6E7 ratio analysis.
Cervical biopsy is a key method to acquire direct evi-
dence of precancerous/cancerous lesions. This process
provides reliable guidance to develop a proper treatment
scenario. However, we and other groups have demon-
strated a rate of missed biopsy, especially in women with
no visible lesions in the cervix [41-44]. In this study, this
rate reached 5.1% during the first-round biopsy and 2.2%
during the second-round biopsy. Because the three biop-
sies were very close in time to one another (within three
months), the missed cases should not be considered
newly developed during the examination interval. A ra-
tional reason for this phenomenon is the “jumping”-style
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cervical lesions, which compel the “multipoint” biopsy to
function in a randomized manner to capture disease sites.
Unlike the cervical biopsy, the HPV integration test adopts
as its experimental material exfoliated cells, which can be
easily obtained by brushing the outer orifice of the cervix.
The obtained exfoliated cells are from all of the layers of
epithelium located in the entire cervical region. Therefore,
this test is more efficient than the multipoint tissue-
punching process of cervical biopsy for acquiring
diseased cells, which makes the HPV integration test a
comprehensive method for assessing cervical lesions. In
our study, after a first round of biopsy, the remaining
undetected cases only accounted for a very small pro-
portion of the women, i.e., 7.3% (5.1% + 2.2%). We dem-
onstrated that, using the HPV integration test, most of
these women could be identified before a second-round
biopsy, while only a few would be missed. The NPVs of
the three techniques were all greater than 99%, and the
PPVs varied between 30% and 45% (Figure 3D). These
PPVs indicate that the efficacy of a second-round biopsy
could be increased by approximately four- to six-fold
(compared to the CIN detection rate during the second-
round biopsy) with the assistance of integration tests.
Moreover, given the fact that, even in the third-round
biopsy, the HPV integration test exhibited a 16% to 36%
PPV, and >1% women were afterwards diagnosed with
precancerous/cancerous lesions, our results suggest that
the HPV-positive women with cervical cytological abnor-
malities, such as HSIL, LSIL, ASC-H and ASC-US, deserve
repeated biopsies to rule out potential life-threatening
lesions [44]. The delay or neglect of this task could lead to
disease progression and poorer prognosis. However, a
ridiculous phenomenon was observed in our study; that is,
the most sensitive technique, DIPS, showed much lower
PPVs as a triage test compared to the two copy number
ratio-based techniques (Figure 3E). To provide a reason-
able explanation, we noted that some integrated/mixed
HPV infection cases, although having no identifiable
precancerous/cancerous lesions, were detected by DIPS
but were otherwise denied by the copy number ratio-
based techniques. The majority of these cases were located
at the highest tertile of the viral load; therefore, these
cases were difficult to detect using only a copy number
ratio-based method (Figure 3D). These cases should
occur during the early stage of integration, as no signifi-
cant changes were found in their affected tissues. They
comprised the major source to undermine the PPV per-
formance of DIPS in cervical lesion sufferers. In addition,
similar PPV phenomena were also observed between the
E1-L1/E6E7 ratio analysis and the E2/E6E7 ratio analysis.
The former displayed PPVs that were 9.1% and 15.9%
higher than those of the latter during the second- and
third-round biopsies, respectively. However, the numberof invalid cases that were produced by the over-sensitive
detection of non-precancerous and -cancerous lesions in
the E1-L1/E6E7 ratio analysis was six greater than was that
produced by the E2/E6E7 ratio analysis during the second-
round biopsy and became equal during the third-round
biopsy (Figure 3D and E and Additional file 2: Figure S3).
Therefore, the improvement of PPVs by the E1-L1/E6E7
ratio analysis should be explained by its increased efficacy in
detecting CIN I-III and/or cervical cancer cases per se but
not the reduced valid cases (refer to Figure 3D). In thus way,
the E1-L1/E6E7 ratio analysis achieved the highest predictive
ability, making it a useful triage test to direct repeated
biopsies in the suspected women.
The clinically collected samples usually need to be pre-
served for a period of time until they can be examined
or re-examined under necessary conditions. A clinically
applicable test, therefore, is expected to be able to main-
tain its detection ability as the sample quality begins to
decrease. We re-examined the DNA extractions of cervical
samples after one-month of preservation at −20°C. A low-
ered technical reproducibility was observed only among
the results of triplicate DIPS (Table 4), while both of the
two copy number ratio-based analyses maintained 100%
detection consistency for three technical repeats. We
postulated that the reason should reside in the different
tolerances of these three techniques to DNA degradation.
The DIPS technique requires high-quality DNA templates
to maintain its detection ability, where no nucleotide nicks
or breaks should exist in the sequences flanking or span-
ning the viral-cellular junctions. Once DNA degradation
occurs, the remaining viral-cellular junction-containing
sequences must be destroyed so that they cannot be amp-
lified by DIPS as effectively as in freshly isolated DNA,
leading to a loss of detection accuracy in the long-term
preserved samples. In contrast, the copy number ratio
analysis can persistently maintain its technical stability
under DNA degradation conditions because the ratios
of each pair of target segments are unaffected in a
homogenously decayed genome DNA background. Re-
garding the individual ratios that comprise the entire
copy number ratio analysis, their CVs were all lower than
10%, which agree with the acknowledged international
standard on the quantitative stability of techniques that
are used for clinical detection [45-47]. A few cases were
missed by the first-round DIPS and were detected by the
second- or third-round DIPS. This phenomenon reflected
the random nature of the DIPS detection. The efficacy of
DIPS depends on the successful ligation between the
adaptors and the ends of the viral-cellular junction-
containing sequences [12]. Sometimes, due to uncertain
reasons (e.g., enzyme inactivation, too short reaction
time and inadequate sample DNA), the ligation process
could fail and lead to missed detection. These technical
or artificial faults were corrected when we repeated the
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the first-round DIPS can be identified and redressed. In
addition, a change in the restriction endonucleases in
DIPS also resulted in the identification of new cases,
reflecting a sequence distance-limited detection ability
of this technique. As we changed the restriction enzyme,
the linear distance between the adapter and primer-binding
sequence site was shortened to a general PCR reachable
range [48,49]; therefore, the viral-cellular junction was
amplified and sequenced. On this aspect, the two copy
number ratio-based techniques hold a natural and
predominant advantage.
Our study of women with single-genotypic HPV infec-
tions has its limitations. Previous studies indicated that
women with multi-genotypic HPV infections can account
for 10% to 20% of the total cervical HPV-positive cases
[17,27]. This population is worthy of specific attention, as
the detection objectives are beyond the ability of presently
available HPV integration tests. Future studies should
focus on developing a PCR array (viral genotypes × ratio
targets) to detect the integration statuses of various HPV
in a multi-genotypically infected woman. Although the
experimental workload could thus be doubled, a more
complete detection coverage on the goal population can
be achieved using this new advanced PCR array-based
copy number ratio-based analysis, whereby a cooperative
effect of different HPV genotypes on the carcinogenesis
of cervical epithelium can be explored and understood.
Moreover, the multiple E1-L1/E6E7 ratio analysis has
adopted four more PCR reactions than those of a traditional
E2/E6E7 ratio analysis, whereas the cost-effectiveness of this
modification is not yet known and should be estimated in
future studies. Nevertheless, compared to DIPS, the cost
of the E1-L1/E6E7 ratio analysis is significantly decreased
(Figure 1B). In light of the similar diagnostic performance as
well as the high detection consistency between the DIPS
and E1-L1/E6E7 ratio analyses (Figures 3A, Additional file 2:
Figure S2, Additional file 1: Tables S2-S5), the advan-
tage of using the E1-L1/E6E7 ratio analysis to serve as
a triage test is convincible, indicating its popularization
in clinical practice.
Conclusions
In conclusion, our study demonstrates that the multiple
E1-L1/E6E7 ratio analysis is more sensitive and predict-
ive than its prototype the E2/E6E7 ratio analysis, and it
is also a more convenient and stable technique if the gold-
standard technique, DIPS, is used as a reference. This
technique is capable of meeting the growing demands
for detecting integrated/mixed HPV infection cases in
the current clinic. Meanwhile, regarding identifying the
high-risk women of cervical cancer and selecting candi-
dates for colposcopy and cervical biopsy, this technique
possesses a substantial value as a triage test, which caneffectively reduce the range of the target population,
thereby concentrating limited medical resources to those
in the most need and ameliorating unnecessary stress
in low-risk women. At last, as a novel, extensible and
broad-spectrum technique, the multiple E1-L1/E6E7 ratio
analysis could be used by more HPV integration-related
studies to explore the epidemiological mechanisms of
cervical cancer that is induced by a score of HPV genotypes.
Additional files
Additional file 1: Supplementary Tables. Table S1 lists the primers,
probes and restriction enzymes that were used in the multigenotypic
DIPS, the E2/E6E7 ratio analysis and the E1-L1/E6E7 ratio analysis in this
study. Table S2 describes the detection results of the three techniques
and compares their consistencies. Tables S3-S5 provides a detailed
comparison of the detection results between each pair of the three
techniques. Tables S6-S30 indicates the detection results of the three
techniques in each individual woman.
Additional file 2: Supplementary Figures. Figure S1 schematically
depicts the principal of DIPS and provides some sequencing-verified
samples of the E2-related and non-E2 HPV integration events. In addition, an
example of the undetected cases of DIPS, which was corrected by changing
a restriction enzyme, is displayed. Figure S2 shows the age-, genotype- and
cervical lesion-related distribution patterns of the integrated/mixed HPV
infection that was detected by the three techniques among the enrolled
women. Figure S3 describes the distribution characteristics of the DIPS-, E2/
E6E7 ratio analysis- and E1-L1/E6E7 ratio analysis-detected cases among the
viral load-cervical lesion two-dimensional space, where the y-axis consists of
three DNA load tertiles, and the x-axis consists of five biopsy-identified lesion
grades.
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